Entellus Medical (ENTL) Raised to “Hold” at ValuEngine
ValuEngine upgraded shares of Entellus Medical (NASDAQ:ENTL) from a sell rating to a hold rating in a research note released on Thursday morning.
ENTL has been the subject of several other reports. Zacks Investment Research cut Entellus Medical from a buy rating to a hold rating in a report on Tuesday, October 31st. BidaskClub raised Entellus Medical from a hold rating to a buy rating in a report on Saturday, August 19th. Piper Jaffray Companies reissued a buy rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, Canaccord Genuity reissued a hold rating and issued a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $20.40.
Shares of Entellus Medical (ENTL) opened at $24.35 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $24.40.
A number of hedge funds have recently modified their holdings of ENTL. Aisling Capital LLC acquired a new position in Entellus Medical during the third quarter worth $9,759,000. Frontier Capital Management Co. LLC raised its holdings in Entellus Medical by 85.0% during the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock worth $14,347,000 after purchasing an additional 397,953 shares during the last quarter. Tekla Capital Management LLC purchased a new position in Entellus Medical during the second quarter worth $5,655,000. Nicholas Company Inc. increased its position in Entellus Medical by 1,052.3% during the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after buying an additional 226,190 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Entellus Medical by 77.8% during the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock worth $5,862,000 after buying an additional 185,833 shares in the last quarter. 78.76% of the stock is owned by hedge funds and other institutional investors.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related stocks with our FREE daily email newsletter.